{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:36:19Z","timestamp":1792154179248,"version":"4.4.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.juro.2010.12.032","type":"journal-article","created":{"date-parts":[[2011,4,10]],"date-time":"2011-04-10T22:09:06Z","timestamp":1302473346000},"page":"1650-1655","source":"Crossref","is-referenced-by-count":410,"title":["A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng\/ml Prostate Specific Antigen Range"],"prefix":"10.1097","volume":"185","author":[{"given":"William J.","family":"Catalona","sequence":"first","affiliation":[{"name":"Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan W.","family":"Partin","sequence":"additional","affiliation":[{"name":"Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Sanda","sequence":"additional","affiliation":[{"name":"Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Klee","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris H.","family":"Bangma","sequence":"additional","affiliation":[{"name":"Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Slawin","sequence":"additional","affiliation":[{"name":"Vanguard Urologic Institute and Texas Prostate Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard S.","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California-Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Loeb","sequence":"additional","affiliation":[{"name":"Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis L.","family":"Broyles","sequence":"additional","affiliation":[{"name":"Beckman Coulter, Inc., Carlsbad, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghyuk S.","family":"Shin","sequence":"additional","affiliation":[{"name":"Beckman Coulter, Inc., Carlsbad, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amabelle B.","family":"Cruz","sequence":"additional","affiliation":[{"name":"Beckman Coulter, Inc., Carlsbad, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Sokoll","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Roberts","sequence":"additional","affiliation":[{"name":"ARUP Laboratories, Department of Pathology, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.N.","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac A.","family":"Mizrahi","sequence":"additional","affiliation":[{"name":"Beckman Coulter, Inc., Carlsbad, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2010.12.032_bib1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0090-4295(02)01875-7","article-title":"Prostate-specific antigen cutoff of 2.6 ng\/ml for prostate cancer screening is associated with favorable pathologic tumor features","volume":"60","author":"Krumholtz","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.juro.2010.12.032_bib2","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2010.12.032_bib3","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0022-5347(17)35233-3","article-title":"Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men","volume":"151","author":"Catalona","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.12.032_bib4","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/clinchem\/37.9.1618","article-title":"Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin","volume":"37","author":"Lilja","year":"1991","journal-title":"Clin Chem"},{"key":"10.1016\/j.juro.2010.12.032_bib5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","article-title":"Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial","volume":"279","author":"Catalona","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2010.12.032_bib6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1373\/clinchem.2003.026823","article-title":"Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer","volume":"50","author":"Mikolajczyk","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.juro.2010.12.032_bib7","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0090-4295(97)00449-4","article-title":"A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum","volume":"50","author":"Mikolajczyk","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.juro.2010.12.032_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0090-4295(03)00138-9","article-title":"Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen","volume":"62","author":"Chan","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.juro.2010.12.032_bib9","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1097\/01.ju.0000095460.12999.43","article-title":"Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng\/ml","volume":"170","author":"Catalona","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.12.032_bib10","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1097\/01.ju.0000127737.94221.3e","article-title":"Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng\/ml prostate specific antigen","volume":"171","author":"Catalona","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.12.032_bib11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0090-4295(02)02398-1","article-title":"Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng\/ml total PSA range: preliminary analysis","volume":"61","author":"Sokoll","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.juro.2010.12.032_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.juro.2008.04.015","article-title":"[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study","volume":"180","author":"Sokoll","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.12.032_bib13","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1158\/1055-9965.EPI-10-0007","article-title":"A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness","volume":"19","author":"Sokoll","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.juro.2010.12.032_bib14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2010.12.032_bib15","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2010.12.032_bib16","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/jnci\/djp278","article-title":"Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005","volume":"101","author":"Welch","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2010.12.032_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the Goteborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.juro.2010.12.032_bib18","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1158\/1078-0432.CCR-09-1263","article-title":"Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer","volume":"15","author":"Makarov","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2010.12.032_bib19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.eururo.2010.02.003","article-title":"Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection","volume":"57","author":"Jansen","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2010.12.032_bib20","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.clinbiochem.2010.04.062","article-title":"Pre-analytical in-vitro stability of [-2]proPSA in blood and serum","volume":"43","author":"Semjonow","year":"2010","journal-title":"Clin Biochem"},{"key":"10.1016\/j.juro.2010.12.032_bib21","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/sim.2459","article-title":"New confidence intervals for the difference between two sensitivities at a fixed level of specificity","volume":"25","author":"Qin","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.juro.2010.12.032_bib22","series-title":"Applied Logistic Regression","author":"Hosmer","year":"1989"},{"key":"10.1016\/j.juro.2010.12.032_bib23","series-title":"The Jackknife, the Bootstrap, and Other Resampling Plans","author":"Efron","year":"1982"},{"key":"10.1016\/j.juro.2010.12.032_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/01621459.1987.10478410","article-title":"Better bootstrap confidence intervals","volume":"82","author":"Efron","year":"1987","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.juro.2010.12.032_bib25","series-title":"The Statistical Evaluation of Medical Tests for Classification and Prediction","author":"Pepe","year":"2003"},{"key":"10.1016\/j.juro.2010.12.032_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.juro.2010.12.032_bib27","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.urology.2004.11.030","article-title":"Additional use of [-2] precursor prostate-specific antigen and \u201cbenign\u201d PSA at diagnosis in screen-detected prostate cancer","volume":"65","author":"de Vries","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2010.12.032_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urolonc.2004.07.017","article-title":"Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer","volume":"23","author":"Naya","year":"2005","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2010.12.032_bib29","unstructured":"Isharwal S, Makarov DV, Sokoll LJ et al: Prostate Health Index and diagnostic biopsy tissue DNA content combination improves accuracy to predict the need for prostate cancer treatment among men enrolled in a proactive surveillance program. Unpublished data."},{"key":"10.1016\/j.juro.2010.12.032_bib30","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.juro.2008.07.036","article-title":"Prostate specific antigen assay standardization bias could affect clinical decision making","volume":"180","author":"Loeb","year":"2008","journal-title":"J Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710053747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710053747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2010.12.032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T02:17:19Z","timestamp":1651198639000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2010.12.032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1016\/j.juro.2010.12.032"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2010.12.032","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}